Peptide Therapeutics Market Report 2026

Peptide Therapeutics Market Overview

• Peptide Therapeutics market size has reached to $49.21 billion in 2025 • Expected to grow to $83.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.2% • Growth Driver: Rising Prevalence Of Chronic Diseases Propels Growth In The Peptide Therapeutics Market • Market Trend: Evonik Breakthrough Cqrex Kc Redefines Cell Culture Processes In The Peptide Therapeutics Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Peptide Therapeutics Market?

Peptide therapeutics refer to a therapeutic approach that uses peptides as medications. Peptides are a distinct family of pharmacological substances that are molecularly situated in between proteins and tiny molecules. Peptides that are found in nature serve a variety of purposes, including those of hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives. Consequently, using peptides as treatments offers a way to target a variety of cells and control their response. The main types of peptide therapeutics are generic and branded. The branded peptide therapeutics are drugs sold under the brand names of large pharma companies that own the patent for these drugs. These are more expensive than generic drugs as they maintain a distinct brand. The peptide therapeutics are administered in several routes such as parenteral, mucosal, oral, and transdermal. They are used for treating cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, and acromegaly.

What Is The Peptide Therapeutics Market Growth Forecast?

The peptide therapeutics market size is expected to see rapid growth in the next few years. It will grow to $83.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to rise of personalized medicine, increasing investment in peptide-based therapeutics, integration of AI in drug discovery, expansion of biologics manufacturing, growth in emerging markets for healthcare solutions. Major trends in the forecast period include targeted peptide drug development, peptide drug delivery innovations, multi-functional peptide therapeutics, natural peptide extraction & synthesis, combination therapies with peptides.

Global Peptide Therapeutics Market Segmentation

1) By Type: Generic, Branded 2) By Route of Administration: Parenteral, Mucosal, Oral, Transdermal 3) By Application: Cancer, Cardiovascular Diseases, Central Nervous Systems, Metabolic Disorders, Infections, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders, Acromegaly, Other Applications Subsegments: 1) By Generic: Generic Peptide Drugs, Biosimilars 2) By Branded: Innovative Peptide Drugs, Patent-Protected Peptides

What Is The Driver Of The Peptide Therapeutics Market?

An increase in the prevalence of chronic diseases is expected to propel the growth of the peptide therapeutics market. Chronic diseases are long-lasting sickness that often cannot be healed, however, they are occasionally curable and controllable. Chronic diseases are increasing due to increased use of tobacco products, poor nutrition, physical inactivity, excessive alcohol use, and others. The use of peptide therapeutics aids in the prevention and treatment of certain chronic diseases. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least one chronic condition would increase by 99.5%, that is 142.66 million, by 2050. Therefore, the increase in the prevalence of chronic diseases is expected to drive the peptide therapeutics industry during the forecast period.

Key Players In The Global Peptide Therapeutics Market

Major companies operating in the peptide therapeutics market are Pfizer Inc., Jhonson & Jhonson, Abbvie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk AS, Teva Pharmaceuticals Industries Ltd., Bachem Holding AG, PolyPeptide Laboratories BV, Arcus Biosciences Inc., Pepscan Therapeutics, Peptech Inc., Peptide Logic Inc., SELLAS Life Sciences Group, Ever Neuro Pharma GmbH, Zealand Pharma AG, PepGen Inc., Pepticom S.A., Peptide Technologies Corporation, SynPeptide Inc., Peptimmune Inc., Merck & Co Inc.

Global Peptide Therapeutics Market Trends and Insights

Major companies operating in the peptide therapeutics market are focused on introducing advanced solutions, such as cell culture process, to gain a competitive edge in the market. Cell culture process is the process of growing cells outside of their natural environment, under controlled conditions which involves isolating cells of interest from living tissue and subsequently maintaining them. For instance, in June 2023, Evonik Industries AG, a German-based specialty chemicals company launched cQrex KC. cQrex KC is next-generation peptide for biopharma applications designed for cell culture process used in the manufacture of biological drugs. It enables cell culture process developers to optimize cystine supply and increase cell culture productivity. cQrex KC supports the development of vaccines, viral vectors, and cell therapies.

What Are Latest Mergers And Acquisitions In The Peptide Therapeutics Market?

In July 2024, AstraZeneca plc, an England-based pharmaceutical and biotechnology company, acquired Amolyt Pharma for $1.05 billion. This acquisition aligns with AstraZeneca's broader strategy to strengthen its capabilities in rare diseases and expand its therapeutic offerings in high-need areas. Amolyt Pharma is a France-based clinical-stage biotechnology company that specializes in developing therapeutic peptides aimed at treating rare endocrine and metabolic diseases.

Regional Insights

North America was the largest region in the peptide therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Peptide Therapeutics Market?

The peptide therapeutics market includes revenues earned by entities by creating drugs to treat a variety of diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Peptide Therapeutics Market Report 2026?

The peptide therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.